These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

59 related items for PubMed ID: 16182164

  • 1. The long-term effect of anti TNF-alpha treatment on temporomandibular joints, oral mucosa, and salivary flow in patients with active rheumatoid arthritis: a pilot study.
    Moen K, Kvalvik AG, Hellem S, Jonsson R, Brun JG.
    Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2005 Oct; 100(4):433-40. PubMed ID: 16182164
    [Abstract] [Full Text] [Related]

  • 2. [Correlation between different clinical activity and anti CC-P (anti-cyclic citrullinated peptide antibodies) titres in rheumatoid arthritis treated with three different tumor necrosis factors TNF-alpha blockers].
    Benucci M, Turchini S, Parrochi P, Boccaccini P, Manetti R, Cammelli E, Manfredi M.
    Recenti Prog Med; 2006 Mar; 97(3):134-9. PubMed ID: 16700418
    [Abstract] [Full Text] [Related]

  • 3. B cell depletion may be more effective than switching to an alternative anti-tumor necrosis factor agent in rheumatoid arthritis patients with inadequate response to anti-tumor necrosis factor agents.
    Finckh A, Ciurea A, Brulhart L, Kyburz D, Möller B, Dehler S, Revaz S, Dudler J, Gabay C, Physicians of the Swiss Clinical Quality Management Program for Rheumatoid Arthritis.
    Arthritis Rheum; 2007 May; 56(5):1417-23. PubMed ID: 17469098
    [Abstract] [Full Text] [Related]

  • 4. Effectiveness of a third tumor necrosis factor-α-blocking agent compared with rituximab after failure of 2 TNF-blocking agents in rheumatoid arthritis.
    Blom M, Kievit W, Donders AR, den Broeder AA, Straten VH, Kuper I, Visser H, Jansen TL, Brus HL, Branten AJ, van de Laar MA, van Riel PL.
    J Rheumatol; 2011 Nov; 38(11):2355-61. PubMed ID: 21885487
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Anti-Ro/SSA antibodies are an independent factor associated with an insufficient response to tumor necrosis factor inhibitors in patients with rheumatoid arthritis.
    Matsudaira R, Tamura N, Sekiya F, Ogasawara M, Yamanaka K, Takasaki Y.
    J Rheumatol; 2011 Nov; 38(11):2346-54. PubMed ID: 21965648
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. The reason for discontinuation of the first tumor necrosis factor (TNF) blocking agent does not influence the effect of a second TNF blocking agent in patients with rheumatoid arthritis.
    Blom M, Kievit W, Fransen J, Kuper IH, den Broeder AA, De Gendt CM, Jansen TL, Brus HL, van de Laar MA, van Riel PL.
    J Rheumatol; 2009 Oct; 36(10):2171-7. PubMed ID: 19723902
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Effectiveness, predictive response factors, and safety of anti-tumor necrosis factor (TNF) therapies in anti-TNF-naive rheumatoid arthritis.
    Fernández-Nebro A, Irigoyen MV, Ureña I, Belmonte-López MA, Coret V, Jiménez-Núñez FG, Díaz-Cordovés G, López-Lasanta MA, Ponce A, Rodríguez-Pérez M, Calero E, González-Santos P.
    J Rheumatol; 2007 Dec; 34(12):2334-42. PubMed ID: 17985409
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. The presence or absence of antibodies to infliximab or adalimumab determines the outcome of switching to etanercept.
    Jamnitski A, Bartelds GM, Nurmohamed MT, van Schouwenburg PA, van Schaardenburg D, Stapel SO, Dijkmans BA, Aarden L, Wolbink GJ.
    Ann Rheum Dis; 2011 Feb; 70(2):284-8. PubMed ID: 21068090
    [Abstract] [Full Text] [Related]

  • 14. The importance of the baseline Disease Activity Score 28 in determining responders and non-responders to anti-TNF in UK clinical practice.
    Smith N, Ding T, Butt S, Gadsby K, Deighton C.
    Rheumatology (Oxford); 2008 Sep; 47(9):1389-91. PubMed ID: 18603597
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. [The impact of therapy with TNF-blockers on health-related quality of life in rheumatoid arthritis patients. A pilot study].
    Abalos Medina GM, Ruiz Villaverde G, Sánchez Cano D, Ruiz Villaverde R, Ramírez Rodrigo J, Raya Álvarez E, Villaverde Gutiérrez C.
    Reumatol Clin; 2011 Sep; 7(3):167-71. PubMed ID: 21794808
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 3.